pentasa endaþarmsdreifa 1 g/100 ml
ferring lægemidler a/s - mesalazinum inn - endaþarmsdreifa - 1 g/100 ml
zoledronic acid mylan
mylan pharmaceuticals limited - zoledronsýra - brot, bein - lyf til að meðhöndla beinsjúkdóma - fyrirbyggja beinagrind atburðum tengdum (sjúkleg beinbrot, hrygg þjöppun, geislun eða skurðaðgerð á að beinum, eða æxli völdum álíka) í fullorðinn sjúklinga með langt illkynja þar bein;meðferð fullorðinn sjúklinga með æxli völdum álíka (tih).
menbutil (genabiline) stungulyf, lausn 100 mg/ml
animedica gmbh - menbutone - stungulyf, lausn - 100 mg/ml
zoledronic acid medac
medac gesellschaft für klinische spezialpräparate mbh - zoledronsýru einhýdrat - fractures, bone; cancer - lyf til að meðhöndla beinsjúkdóma - forvarnir vegna tengdra beinagrindar (sjúkdómsbrot, mænuþrýstingur, geislun eða skurðaðgerð í bein eða æxlisfrumna blóðkalsíumhækkun) hjá fullorðnum sjúklingum með langt gengið illkynja sjúkdóma sem fela í sér bein. meðferð fullorðinn sjúklinga með æxli völdum álíka (tih).
nipruss innrennslisstofn, lausn 60 mg
oresund pharma aps - sodium nitroprusside dihydrate - innrennslisstofn, lausn - 60 mg
cinveron stungulyf, lausn 2 mg/ml
williams & halls ehf - ondansetronum hýdróklóríð - stungulyf, lausn - 2 mg/ml
albuman innrennslislyf, lausn 40 g/l
prothya biosolutions netherlands b.v. - human albumin - innrennslislyf, lausn - 40 g/l
epirubicin actavis stungulyf, lausn 2 mg/ml
actavis group ptc ehf. - epirubicinum hýdróklóríð - stungulyf, lausn - 2 mg/ml
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - Æxlishemjandi lyf - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
cefotaxim navamedic (cefotaxim villerton) stungulyfsstofn, lausn 1 g
navamedic asa - cefotaximum natríum - stungulyfsstofn, lausn - 1 g